FY2017 EPS Estimates for Esperion Therapeutics, Inc. Increased by Jefferies Group (ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Jefferies Group raised their FY2017 EPS estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday. Jefferies Group analyst M. Yee now expects that the biopharmaceutical company will post earnings of ($7.43) per share for the year, up from their previous estimate of ($7.45). Jefferies Group currently has a “Buy” rating and a $85.00 target price on the stock. Jefferies Group also issued estimates for Esperion Therapeutics’ Q4 2017 earnings at ($1.86) EPS and FY2018 earnings at ($8.54) EPS.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same quarter last year, the company posted ($0.77) earnings per share. TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for Esperion Therapeutics, Inc. Increased by Jefferies Group (ESPR)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/fy2017-eps-estimates-for-esperion-therapeutics-inc-increased-by-jefferies-group-espr/1691907.html.
A number of other research firms also recently issued reports on ESPR. Northland Securities restated a “buy” rating and set a $72.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Deutsche Bank AG set a $64.00 price objective on Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cowen and Company assumed coverage on Esperion Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $64.00 price objective on the stock. Finally, Bank of America Corporation reaffirmed a “neutral” rating and set a $60.00 price objective on shares of Esperion Therapeutics in a research report on Friday, August 11th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $58.92.
Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at $48.40 on Thursday. Esperion Therapeutics has a 52 week low of $10.30 and a 52 week high of $57.40.
A number of hedge funds and other institutional investors have recently bought and sold shares of ESPR. Meditor Group Ltd lifted its holdings in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares in the last quarter. State Street Corp lifted its holdings in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after purchasing an additional 1,093,292 shares in the last quarter. Discovery Capital Management LLC CT lifted its holdings in Esperion Therapeutics by 152.9% in the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after purchasing an additional 583,529 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in Esperion Therapeutics in the 2nd quarter worth approximately $14,748,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in Esperion Therapeutics by 12,603.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock worth $10,098,000 after purchasing an additional 199,890 shares in the last quarter. 90.05% of the stock is currently owned by institutional investors.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.